Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics executive Sean Maduck reported equity award activity and related tax withholding. On March 2, 2026, he acquired two grants of common stock totaling 908 shares, including 454 purchase-plan shares priced under a company purchase plan and 454 shares granted at no cost as an award. On March 3, 2026, 110 shares were withheld by Corcept at a price of $35.97 per share to cover tax obligations tied to vesting restricted stock units, leaving 8,977 common shares held directly.
The filing also lists indirect ownership stakes through several entities, including the Sean and Molly Maduck Living Trust, MMM 2025, LLC, two SNM Grantor Retained Annuity Trusts, and Duckhill Capital, LLC. Maduck disclaims beneficial ownership of Duckhill Capital, LLC shares beyond his pecuniary interest.
Corcept Therapeutics’ Chief Business Officer Gary Charles Robb reported routine equity compensation activity in the company’s common stock. On March 2, 2026, he acquired 499 shares at $35.97 per share under a purchase plan established pursuant to the 2024 Incentive Award Plan, and received an additional 499-share restricted stock award at no stated cost. These awards include unvested restricted stock that will fully vest on the one-year anniversary of each grant if specified service and ownership conditions are met.
On March 3, 2026, 121 shares were disposed of at $35.97 per share to satisfy tax withholding obligations tied to vesting restricted stock units, meaning the shares were withheld by the company rather than sold in the open market. After these transactions, Robb directly held 79,503 shares and indirectly oversaw 11,571 shares held in a custodial account for a child under the Uniform Transfers to Minors Act.
Corcept Therapeutics Chief Development Officer William Guyer reported two stock acquisitions. On March 2, 2026, he acquired 498 shares of common stock at $35.97 per share under a purchase plan and received an additional 498 restricted shares at no cost. After these transactions, he directly owned 2,231 shares, including unvested restricted stock awards that vest after one year if specified service and ownership conditions are met.
Corcept Therapeutics Chief Financial Officer Atabak Mokari reported a mix of share awards and tax withholding transactions in company stock. On March 2, 2026, he acquired 397 shares of common stock in one grant/award transaction at $35.97 per share and another 397-share grant at a stated price of $0.00 per share.
On March 3, 2026, 96 shares were disposed of in a tax-withholding transaction at $35.97 per share to cover obligations tied to vesting restricted stock units. Following these transactions, he directly owned 15,257 shares of common stock, including unvested restricted stock awards subject to future vesting conditions.
Corcept Therapeutics: Rule 144 notice of proposed sale of common stock. The filing lists a planned sale of 20,000 common shares on 03/04/2026 by Stifel Nicolaus & Company Inc. via a stock option exercise for cash. The filing also records prior sales by William Guyer of 20,000 shares on 02/03/2026 for $817,333.00 and 20,000 shares on 01/06/2026 for $703,655.00.
Lyon Joseph Douglas reported acquisition or exercise transactions in this Form 4 filing.
Corcept Therapeutics reported that officer Joseph Douglas Lyon received a grant of stock options covering 140,000 shares of the company’s stock. The options were awarded as a form of equity compensation and are held directly by Lyon.
According to the terms, the options begin vesting on February 27, 2026 and will vest in equal monthly installments over a four-year period, as long as Lyon continues providing service through each vesting date. This structure is designed to spread the potential ownership benefit over time and align it with ongoing service.
BELANOFF JOSEPH K reported acquisition or exercise transactions in this Form 4 filing.
Corcept Therapeutics reported that Chief Executive Officer Joseph K. Belanoff received a grant of stock options covering 460,000 shares on February 27, 2026. These options give him the right to buy company stock and are structured as long-term incentive compensation.
The options vest in equal installments on each monthly anniversary of February 27, 2026, over a four-year period, and each vesting installment is conditioned on his continued service through the applicable vesting date.
Corcept Therapeutics' Chief Financial Officer receives a new stock option grant. On February 27, 2026, CFO Atabak Mokari was granted stock options covering 140,000 shares of Corcept Therapeutics common stock at an exercise price of $0.00 per share, recorded as a direct ownership position.
The options vest in equal monthly installments over four years, starting from the monthly anniversary of February 27, 2026, and require the executive’s continued service through each vesting date. After this grant, the reported derivative holdings from this award total 140,000 options.
Corcept Therapeutics reported that officer Sean Maduck received a grant of stock options covering 140,000 shares of the company’s stock. The award was recorded as an acquisition of derivative securities at no cash cost on the grant date.
According to the terms, these options vest in equal installments on each monthly anniversary of February 27, 2026 over a four-year period, and vesting requires Mr. Maduck’s continued service through each vesting date. Following this grant, he is shown as holding stock options for 140,000 shares directly.
Corcept Therapeutics reported that Chief Scientific Officer Hazel Hunt received a grant of stock options. The award covers 140,000 stock options with a stated exercise price of $0.00 per share, reflecting a compensatory equity grant rather than an open-market purchase.
These options begin vesting from February 27, 2026 and will vest in equal installments on each monthly anniversary of that date over a four-year period. Vesting is conditioned on Hunt’s continued service through each vesting date, tying the award to long-term employment and performance.